Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Robert L. Ferris et al.|JAMA Oncology|2023Cited by 73
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumabPeter Grell, Marek Svoboda|International Journal of Oncology|2012Cited by 22
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.Sumanta Kumar Pal, Laurence Albigès, Filippo de Braud et al.|Journal of Clinical Oncology|2024Cited by 9